ATARA BIOTHERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$249.92 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$249.92M, a 757.30% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $42.97M, a 88.56% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $6.62M, a 81.12% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $11.10M, a 26.26% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $98.71M, a 17.87% increase from fiscal 2016.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $83.74M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$220.13M.
- ATARA BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$83.36M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 4 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$249.92M 10-Q · filed 2018-05-08 | -$206.95M derived: sum of 2 quarters · filed 2018-05-08 | -$200.33M derived: sum of 3 quarters · filed 2018-05-08 | -$189.23M derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2017-12-31 | $42.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $49.59M derived: sum of 2 quarters · filed 2018-02-27 | $60.69M derived: sum of 3 quarters · filed 2018-02-27 | $98.71M 10-K · filed 2018-02-27 | |||
| 2017-09-30 | $6.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $17.72M derived: sum of 2 quarters · filed 2017-11-09 | $55.74M 10-Q · filed 2017-11-09 | $78.53M derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2017-06-30 | $11.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $49.12M 10-Q · filed 2017-08-07 | $71.91M derived: sum of 3 quarters · filed 2018-05-08 | $106.95M derived: sum of 4 quarters · filed 2018-05-08 | |||
| 2017-03-31 | $38.02M 10-Q · filed 2018-05-08 | $36.82M 10-Q · filed 2017-05-04 | $60.81M derived: sum of 2 quarters · filed 2018-05-08 | $95.85M derived: sum of 3 quarters · filed 2018-05-08 | $110.90M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2016-12-31 | $22.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $57.82M derived: sum of 2 quarters · filed 2018-02-27 | $72.88M derived: sum of 3 quarters · filed 2018-02-27 | $83.74M 10-K · filed 2018-02-27 | |||
| 2016-09-30 | $35.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $50.09M derived: sum of 2 quarters · filed 2017-11-09 | $60.95M 10-Q · filed 2017-11-09 | $41.53M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $15.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $25.92M 10-Q · filed 2017-08-07 | $6.50M derived: sum of 3 quarters · filed 2018-02-27 | -$146.39M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $10.86M 10-Q · filed 2017-05-04 | -$8.56M derived: sum of 2 quarters · filed 2018-02-27 | -$161.44M derived: sum of 3 quarters · filed 2018-02-27 | -$195.83M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$19.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$172.31M derived: sum of 2 quarters · filed 2018-02-27 | -$206.69M derived: sum of 3 quarters · filed 2018-02-27 | -$220.13M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | -$152.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$187.28M derived: sum of 2 quarters · filed 2016-11-04 | -$200.71M 10-Q · filed 2016-11-04 | -$257.64M derived: sum of 4 quarters · filed 2017-03-09 | |||
| 2015-06-30 | -$34.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$47.82M 10-Q · filed 2016-08-08 | -$47.82M 10-Q · filed 2015-08-07 | -$104.76M derived: sum of 3 quarters · filed 2017-03-09 | -$106.19M derived: sum of 4 quarters · filed 2017-03-09 | ||
| 2015-03-31 | -$13.43M 10-Q · filed 2016-05-06 | -$70.37M derived: sum of 2 quarters · filed 2017-03-09 | -$71.80M derived: sum of 3 quarters · filed 2017-03-09 | -$74.38M derived: sum of 4 quarters · filed 2017-03-09 | |||
| 2014-12-31 | -$56.94M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$58.37M derived: sum of 2 quarters · filed 2017-03-09 | -$60.95M derived: sum of 3 quarters · filed 2017-03-09 | -$83.36M 10-K · filed 2017-03-09 | |||
| 2014-09-30 | -$1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$4.01M derived: sum of 2 quarters · filed 2015-11-06 | -$26.43M 10-Q · filed 2015-11-06 | -$26.43M derived: sum of 4 quarters · filed 2016-03-04 | |||
| 2014-06-30 | -$2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$24.99M 10-Q · filed 2015-08-07 | -$24.99M derived: sum of 3 quarters · filed 2016-03-04 | ||||
| 2014-03-31 | -$22.41M 10-Q · filed 2015-05-11 | -$22.41M derived: sum of 2 quarters · filed 2016-03-04 | |||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | -$3.00K 10-K · filed 2016-03-04 | |||||
| 2013-09-30 | -$3.00K 10-Q · filed 2014-11-12 | ||||||
| 2012-12-31 | -$9.00K 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |